Christian W. Cox
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christian W. Cox has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Abdellatif Tazi
Université Paris Cité, Institut Cochin, UMR INSERM U1016-CNRS 8104, Phagocytes and Tumour Immunology Lab, Centre National des Référence des Histiocytoses, Service de Pneumologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
1 shared publication - Eli Louis Diamond
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY
1 shared publication - Gaurav Goyal
Division of Hematology and Oncology University of Alabama at Birmingham Birmingham Alabama USA
1 shared publication - Gregory Kaltsas
1st Propaedeutic Department of Internal Medicine National and Kapodistrian University of Athens Athens Greece
1 shared publication - Jan A. M. van Laar
13Department of Internal Medicine, Section Clinical Immunology and Allergology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands
1 shared publication Jason R. Young
Department of Radiology, Mayo Clinic, Rochester, MN
1 shared publication
Latest Publications
- Top Cited PapersOpen Access
- 28 April 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (17) , 2601-2621
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults
Langerhans cell histiocytosis (LCH) can affect children and adults with a wide variety of clinical manifestations, including unifocal, single-system multifocal, single-system pulmonary (smoking-associated), or multisystem disease. The existing paradigms in the management of LCH in adults are mostly derived from the pediatric literature. Over the last decade, the discovery of clonality and MAPK-ERK pathway mutations in most cases led to the recognition of LCH as a hematopoietic neoplasm, opening the doors for treatment with targeted therapies. These advances have necessitated an update of the existing recommendations for the diagnosis and treatment of LCH in adults. This document presents consensus recommendations that resulted from the discussions at the annual Histiocyte Society meeting in 2019, encompassing clinical features, classification, diagnostic criteria, treatment algorithm, and response assessment for adults with LCH. The recommendations favor the use of 18F-Fluorodeoxyglucose positron emission tomography-based imaging for staging and response assessment in the majority of cases. Most adults with unifocal disease may be cured by local therapies, while the first-line treatment for single-system pulmonary LCH remains smoking cessation. Among patients not amenable or unresponsive to these treatments and/or have multifocal and multisystem disease, systemic treatments are recommended. Preferred systemic treatments in adults with LCH include cladribine or cytarabine, with the emerging role of targeted (BRAF and MEK inhibitor) therapies. Despite documented responses to treatments, many patients struggle with a high symptom burden from pain, fatigue, and mood disorders that should be acknowledged and managed appropriately.
- 28 April 2022
- Published by American Society of Hematology in Blood
- Vol. 139 (17) , 2601-2621
Top Cited PapersOpen AccessInternational expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults
Langerhans cell histiocytosis (LCH) can affect children and adults with a wide variety of clinical manifestations, including unifocal, single-system multifocal, single-system pulmonary (smoking-associated), or multisystem disease. The existing paradigms in the management of LCH in adults are mostly derived from the pediatric literature. Over the last decade, the discovery of clonality and MAPK-ERK pathway mutations in most cases led to the recognition of LCH as a hematopoietic neoplasm, opening the doors for treatment with targeted therapies. These advances have necessitated an update of the existing recommendations for the diagnosis and treatment of LCH in adults. This document presents consensus recommendations that resulted from the discussions at the annual Histiocyte Society meeting in 2019, encompassing clinical features, classification, diagnostic criteria, treatment algorithm, and response assessment for adults with LCH. The recommendations favor the use of 18F-Fluorodeoxyglucose positron emission tomography-based imaging for staging and response assessment in the majority of cases. Most adults with unifocal disease may be cured by local therapies, while the first-line treatment for single-system pulmonary LCH remains smoking cessation. Among patients not amenable or unresponsive to these treatments and/or have multifocal and multisystem disease, systemic treatments are recommended. Preferred systemic treatments in adults with LCH include cladribine or cytarabine, with the emerging role of targeted (BRAF and MEK inhibitor) therapies. Despite documented responses to treatments, many patients struggle with a high symptom burden from pain, fatigue, and mood disorders that should be acknowledged and managed appropriately.
- 1 October 2017
- Published by Elsevier in Academic Radiology
- Vol. 24 (10) , 1325-1326
Andragogic Approaches to Continuing Medical Education
- 1 October 2017
- Published by Elsevier in Academic Radiology
- Vol. 24 (10) , 1325-1326
Andragogic Approaches to Continuing Medical Education
- 1 April 2015
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 12 (4) , 327-328
Coaching: A Key Model of Leadership
- 1 April 2015
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 12 (4) , 327-328
Coaching: A Key Model of Leadership